Literature DB >> 22763615

Pergolide block of the cloned Kv1.5 potassium channels.

Imju Jeong1, Bok Hee Choi, Sang June Hahn.   

Abstract

Pergolide mesylate, an ergot-derivative dopamine receptor agonist, is prescribed for the management of patients with Parkinson's disease. Pergolide caused vasoconstriction in a pulmonary artery. Kv1.5 channel is highly expressed in pulmonary arterial smooth muscle cells, where it plays an important role as a determinant of vascular tone. In the present study, we investigated the effects of pergolide on Kv1.5 stably expressed in Chinese hamster ovary cells using the whole-cell patch-clamp technique. The Kv1.5 block by pergolide was concentration-, time-, voltage-, and use-dependent. Pergolide blocked Kv1.5 currents in a concentration-dependent manner, with an IC(50) value of 15.4 μM and a Hill coefficient of 1.7. The activation and inactivation of Kv1.5 were significantly accelerated by pergolide in a concentration-dependent manner. The apparent association and dissociation rate constants were 0.43 μM(-1) s(-1) and 8.34 s(-1), respectively, with a K (D) value of 19.1 μM. Pergolide slowed deactivation kinetics of Kv1.5, resulting in a tail crossover phenomenon. The block of Kv1.5 by pergolide was voltage-dependent, increasing significantly at test potentials from -10 to +10 mV, whereas the current was reduced slightly with a shallower voltage dependence in the range between +20 and +50 mV (δ = 0.34). There was a significant hyperpolarizing shift in the voltage dependence of steady-state inactivation of Kv1.5. Pergolide produced a use-dependent Kv1.5 block at 1 and 2 Hz, and also slowed the time course for recovery from inactivation. These results suggest that pergolide has an affinity for the open and inactivated states of Kv1.5 channels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763615     DOI: 10.1007/s00210-012-0776-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  42 in total

Review 1.  Acute oxygen-sensing mechanisms.

Authors:  E Kenneth Weir; José López-Barneo; Keith J Buckler; Stephen L Archer
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

2.  Molecular basis and function of voltage-gated K+ channels in pulmonary arterial smooth muscle cells.

Authors:  X J Yuan; J Wang; M Juhaszova; V A Golovina; L J Rubin
Journal:  Am J Physiol       Date:  1998-04

3.  Cardiac effects of pergolide.

Authors:  M Leibowitz; A Lieberman; M Goldstein; A Neophytides; M Kupersmith; G Gopinathan; S Mehl
Journal:  Clin Pharmacol Ther       Date:  1981-12       Impact factor: 6.875

Review 4.  Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.

Authors:  Ursula Ravens; Erich Wettwer
Journal:  Cardiovasc Res       Date:  2010-12-15       Impact factor: 10.787

5.  Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension.

Authors:  Carmelle V Remillard; Donna D Tigno; Oleksandr Platoshyn; Elyssa D Burg; Elena E Brevnova; Diane Conger; Ann Nicholson; Brinda K Rana; Richard N Channick; Lewis J Rubin; Daniel T O'connor; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2007-01-31       Impact factor: 4.249

6.  Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction.

Authors:  Zhigang Hong; Andrew J Smith; Stephen L Archer; Xi-Chen Wu; Daniel P Nelson; Douglas Peterson; Gerhard Johnson; E Kenneth Weir
Journal:  Circulation       Date:  2005-08-29       Impact factor: 29.690

Review 7.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

8.  K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes.

Authors:  M T Slawsky; N A Castle
Journal:  J Pharmacol Exp Ther       Date:  1994-04       Impact factor: 4.030

9.  Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.

Authors:  Judit Horvath; Robin D Fross; Galit Kleiner-Fisman; René Lerch; Hans Stalder; Suzanne Liaudat; William J Raskoff; Keith D Flachsbart; Harry Rakowski; Jean-Claude Pache; Pierre R Burkhard; Anthony E Lang
Journal:  Mov Disord       Date:  2004-06       Impact factor: 10.338

Review 10.  Cardiovascular autonomic dysfunction in Parkinson's disease.

Authors:  Tjalf Ziemssen; Heinz Reichmann
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181

View more
  2 in total

1.  Inhibitory effects of hesperetin on Nav1.5 channels stably expressed in HEK 293 cells and on the voltage-gated cardiac sodium current in human atrial myocytes.

Authors:  Huan Wang; Hong-Fei Wang; Hao Zhang; Chen Wang; Yu-Fang Chen; Rong Ma; Ji-Zhou Xiang; Xin-Ling Du; Qiang Tang
Journal:  Acta Pharmacol Sin       Date:  2016-10-03       Impact factor: 6.150

2.  Effects of neferine on Kv4.3 channels expressed in HEK293 cells and ex vivo electrophysiology of rabbit hearts.

Authors:  Chen Wang; Yu-fang Chen; Xiao-qing Quan; Huan Wang; Rui Zhang; Jun-hua Xiao; Jia-ling Wang; Cun-tai Zhang; Ji-zhou Xiang; Qiang Tang
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.